Stiff Muscles Are Characterized by __________
Stiff Person Syndrome
NORD gratefully acknowledges Scott D. Newsome, Do, FAAN, Associate Professor of Neurology, Director of Stiff Person Syndrome Center, Johns Hopkins School of Medicine, for assistance in the preparation of this study.
Synonyms of Potent Person Syndrome
- Moersch-Woltman syndrome
- stiff-man syndrome
- SMS
- SPS
Subdivisions of Strong Person Syndrome
- classic stiff person syndrome
- focal strong person syndrome
- jerking strong person syndrome
- progressive encephalomyelitis with rigidity and myoclonus (PERM)
- paraneoplastic-related stiff person syndrome
General Discussion
Stiff-person syndrome (SPS) is a rare acquired neurological disorder characterized by progressive muscle stiffness (rigidity) and repeated episodes of painful musculus spasms. Muscular rigidity often fluctuates (i.e., grows worse and then improves) and unremarkably occurs forth with the muscle spasms. Spasms may occur randomly or exist triggered by a multifariousness of different events including a sudden noise or low-cal physical contact. In most cases, other neurological signs or symptoms practice non occur. The severity and progression of SPS varies from one person to another. If left untreated, SPS tin can potentially progress to crusade difficulty walking and significantly affect a person’s ability to perform routine, daily tasks. Although the exact cause of SPS is unknown, it is believed to exist an autoimmune disorder and sometimes occurs along with other autoimmune disorders.
Stiff-person syndrome has been described in the medical literature nether many dissimilar, confusing names. Originally described as stiff-man syndrome, the name was changed to reflect that the disorder tin bear upon individuals of any age and of either gender. In fact, most individuals with the condition are women. Potent-person syndrome is considered by many researchers to exist a spectrum of disease ranging from the involvement of just one expanse of the body to a widespread, rapidly progressive class that too includes involvement of the brain stem and spinal cord (PERM).
Scroll back upwards to restore default view.
Signs & Symptoms
The feature findings associated with SPS are progressive, fluctuating muscular rigidity that occurs along with muscle spasms. The severity and progression of SPS can vary from ane person to another. The symptoms commonly develop over a period of months and may remain stable for many years or slowly worsen. In some people, symptoms can be stabilized through medication. Affected individuals should talk to their physician and medical team about their specific case, associated symptoms and overall prognosis.
In many cases, SPS begins slowly over several months or a few years. Affected individuals may initially experience aching discomfort, stiffness, or pain, especially in the lower back or legs (predominantly classic type). Early on on, stiffness may come and go, but it gradually becomes fixed. The shoulders, neck, and hips may also be affected. As the illness progresses, stiffness of the leg muscles develops, and is ofttimes more pronounced on i side than the other (asymmetrical). This leads to a irksome, strong manner of walking. As stiffness increases, afflicted individuals may develop a hunched or slouched posture due to outward curving of the upper spine (kyphosis) or an arched back due to inward curving of the lower spine (hyperlordosis). In some individuals, stiffness may progress to involve the arms or face.
In addition to muscular rigidity/stiffness, individuals with SPS also develop muscle spasms, which may occur for no credible reason (spontaneously) or in response to various triggering events (i.eastward., stimuli). Spasms tin can be triggered past unexpected or loud noises, minor physical contact, cold environments, stress or situations that cause a heightened emotional response. Muscle spasms are often very painful and normally worsen existing stiffness. The spasms may involve the entire torso or only a specific region. The legs are often involved, which may lead to falls. Spasms of abdominal muscles may pb to individuals feeling full faster than normal (early on satiety) leading to unintended weight loss. Spasms involving the chest and respiratory muscles tin exist serious, potentially requiring emergency medical treatment with ventilatory support. Spasms may last several minutes, but occasionally final for hours. Sudden withdrawal of medication in individuals with SPS may result in a life-threatening situation with overwhelmingly astringent muscle spasms. Sleep commonly suppresses the frequency of contractions.
In some cases, SPS becomes astringent enough to bear upon an individual’s power to perform daily activities and routines. Some individuals may need to use an assistance device such as a pikestaff, walker or wheelchair. Some affected individuals feel uncontrollable feet when they need to cantankerous large, open areas unassisted (agoraphobia) and go reluctant to go exterior. If left untreated, SPS can potentially progress to cause significant disability or life-threatening complications such as respiratory compromise.
SPS may be associated with other autoimmune disorders more frequently than would exist regularly expected to occur in the general population. The most mutual associated condition is diabetes. Less commonly, afflicted individuals may also develop inflammation of the thyroid (thyroiditis), pernicious anemia and vitiligo. Pernicious anemia is characterized by low levels of red bloods cells due to the torso’s disability to absorb vitamin B12 from the gastrointestinal tract. Vitiligo is a pare condition in which loss of color (pigmentation) of areas of peel results in the development of abnormal white patches. Clinical reports indicate that individuals with SPS also have an increased incidence of epilepsy.
Several variants of SPS have been reported in the medical literature suggesting that SPS represents a spectrum of disease ranging from the interest of i specific, localized area to widespread involvement. These variants include stiff-limb syndrome, jerking potent-person syndrome, progressive encephalomyelitis with rigidity and myoclonus, and paraneoplastic-related SPS. These variants are sometimes collectively referred to as “stiff-person plus syndromes”.
Strong-limb syndrome is characterized past the localized involvement of one limb, usually a leg. The stiffness and muscle spasms are extremely similar to those found in archetype stiff-person syndrome. Stiff-limb syndrome may progress to eventually bear upon both legs and may cause difficulty walking. Some individuals may eventually develop archetype stiff-person syndrome or variant SPS. When SPS affects only i specific expanse of the torso, it may as well exist referred to as focal or partial stiff-person syndrome.
Jerking stiff-person syndrome is characterized by muscles stiffness and spasms commonly affecting the legs. Affected individuals too develop involvement of the brainstem, which can cause myoclonus. Myoclonus is a general term used to describe the sudden, involuntary jerking of a muscle or group of muscles caused by musculus contractions (positive myoclonus) or muscle relaxation (negative myoclonus). The twitching or jerking of muscles cannot be controlled past the person experiencing it. Only a handful of cases of jerking stiff-person syndrome take been described in the medical literature.
Progressive encephalomyelitis with rigidity and myoclonus (PERM) is characterized by stiffness and painful muscles that are like to those seen in individuals with archetype potent-person syndrome. PERM is more than rapidly progressive than other forms of SPS; onset of symptoms usually occurs over several weeks. Stiffness and spasms may occur along with, before or afterward the evolution of other symptoms including vertigo, a lack of coordination of voluntary muscles (ataxia), and difficulty speaking (dysarthria). In some cases, the cranial fretfulness may also get involved causing paralysis of certain eye muscles (ophthalmoplegia), rapid, involuntary eye movements (nystagmus), difficulty swallowing (dysphagia), and hearing loss. PERM is considered a distinct disorder from classic SPS and some feel that information technology is a singled-out condition all together. There is no evidence that SPS will inevitably evolve into PERM.
Paraneoplastic-related stiff-person syndrome is a rare disorder that affects the nervous organisation in some individuals with cancer, specially individuals with cancer of the lungs or breast. The disorder is characterized by stiffness and rigidity, along with painful spasms. Symptoms usually begin in the muscles of the lower dorsum and legs, although some individuals experience neck and upper torso symptoms offset. The disorder may grow progressively worse eventually affecting the arms and other parts of the torso. Painful muscle spasms tin can be worsened or triggered by a variety of events including anxiety, loud or unexpected noises or lite physical contact. Paraneoplastic stiff-person syndrome is thought to be immune-mediated and is typically associated with a dissimilar auto-antibody (called anti-amphiphysin) than is institute in individuals with archetype strong-person syndrome. This antibody is usually found in the blood and spinal fluid of affected individuals. (For more than data on this disorder, choose “paraneoplastic neurologic syndromes” as your search term in the Rare Disease Database.)
Causes
The exact cause of SPS is non known. Some studies in the medical literature point that it may be an autoimmune disorder. Autoimmune disorders are caused when the body’due south natural defenses (e.1000., antibodies) against “strange” or invading organisms begin to attack healthy tissue for unknown reasons.
Most of those affected accept antibodies to glutamic acid decarboxylase (GAD), a protein in inhibitory nervus cells that is involved in the creation (synthesis) of the main inhibitory neurotransmitter called gamma-aminobutyric acrid (GABA). GABA helps control muscle movement and prevent hyperexcitibility within the brain and spine. The symptoms of SPS may develop when the allowed system mistakenly attacks certain nerve cells (neurons) that produce GAD leading to a deficiency of GABA in the torso.
Less commonly, individuals with SPS will have antibodies to amphiphysin, a poly peptide involved in the transmission of signals from 1 nerve jail cell to another. In these individuals, breast cancer is quite prevalent.
The exact office that deficiency of GAD plays in the evolution of SPS is not fully understood. Antibodies to GAD-65 are associated with several other disorders including diabetes. In fact, GAD-65 is the nearly common antibody produced by people with autoimmune diabetes and many people have these antibodies in that context. In some individuals with SPS no antibodies to GAD are detectable. The cause of SPS in these individuals may ultimately be unknown (idiopathic), merely testing for other causes (e.g. amphiphysin antibodies) is unremarkably appropriate. More research is necessary to determine the exact, underlying mechanisms that ultimately cause SPS and the exact role that anti-GAD antibodies play in the development and progression of the disorder.
Affected Populations
SPS is an extremely rare disorder. The verbal incidence and prevalence of SPS is unknown, although one judge places the incidence at approximately 1 in one,000,000 individuals in the general population. The distribution of SPS between men and women indicates a female predominance. SPS usually becomes apparent onetime between 30-lx years of age. However, SPS has been reported to occur in children and older adults as well.
SPS was first described in the medical literature past doctors Moersch and Woltman in 1956 as strong-human being syndrome. The disorder is now known as stiff-person syndrome to reflect that the disorder affects individuals of any age and both genders.
Diagnosis
A diagnosis of SPS is made based upon identification of characteristic symptoms, a detailed patient history, and a thorough clinical evaluation. Additional tests can be used to back up a diagnosis and to rule out other weather. Such tests include screening tests to detect the presence of antibodies confronting GAD-65, antibodies against amphiphysin (which are associated with paraneoplastic SPS) and an electromyography (EMG), a test that records electrical activeness in skeletal (voluntary) muscles at rest and during musculus contraction. An EMG can demonstrate continuous muscle motor unit of measurement firing in strong muscles, which is characteristic of SPS. High doses of diazepam will suppress the characteristic EMG results.
Standard Therapies
Handling
The treatment of SPS is directed toward the specific symptoms that are apparent in each individual which often requires a multifaceted approach including non-medication interventions (stretching, oestrus therapy, aqua therapy, massage therapy, acupuncture, etc). Drugs that are considered GABA-ergic agonists therapies such every bit benzodiazepines, specifically diazepam and clonazepam, are used to treat muscle stiffness and episodic spasms. Afflicted individuals may as well benefit from baclofen, usually given in improver to benzodiazepines. Other medications reported to have benefit in a small number of individuals include anti-seizure (anticonvulsant) drugs including vigabatrin, valproate, pregabalin, and gabapentin.
Peer-reviewed clinical studies take shown that intravenous immunoglobulin (IVIG) is effective and well-tolerated in improving the symptoms normally associated with SPS. IVIG is commonly used as a therapy for immune-mediated disorders equally SPS is believed to be. IVIG, under certain weather, has been associated with increased risks for stroke and center attacks and can rarely crusade kidney injury and meningitis. Handling should be prescribed only subsequently a discussion of the bellboy risks and benefits. More enquiry is necessary to determine the long-term condom and effectiveness of IVIG for the treatment of individuals with SPS.
In that location are classes of medications that should be avoided in SPS, including serotonin-norepinephrine reuptake inhibitors (SNRIs; i.due east, tricyclic antidepressants and duloxetine) and opioids. SNRIs accept previously been shown to worsen the EMG activity and clinical symptoms in SPS. Opioids are not recommended for hurting control considering most individuals with SPS are on benzodiazepines. Mixing these two classes of medications can lead to severe respiratory low and death.
Investigational Therapies
Several unlike immune therapies accept been used to treat individuals with SPS beyond IVIG including plasmapheresis, corticosteroids, rituximab, and oral immunosuppressive drugs. Other therapies are being evaluated including non-myeloablative and myeloablative stem prison cell therapies.
Plasmapheresis may be of benefit in individuals with SPS. This procedure is a method for removing unwanted substances (toxins, bad antibodies, metabolic substances, plasma parts) from the blood. Blood is removed from an afflicted private and claret cells are separated from plasma. The plasma is then replaced with other human being plasma or albumin.
This therapy remains under investigation to clarify side effects and effectiveness. More enquiry is needed to make up one’s mind what role plasmapheresis may play in the treatment of individuals with SPS.
Data on current clinical trials is posted on the Internet at world wide web.clinicaltrials.gov. All studies receiving U.S. Regime funding, and some supported past private industry, are posted on this regime web site.
For information about clinical trials being conducted at the NIH Clinical Middle in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Electronic mail: [e-mail protected]
Some electric current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/for-patients-and-families/information-resources/news-patient-recruitment/
For information most clinical trials sponsored by private sources, contact:
www.centerwatch.com
For data most clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
NORD Fellow member Organizations
- Stiff Person Syndrome Inquiry Foundation
- 8621 Burdette Road
- Bethesda, MD 20817 USA
- Email:
[email protected] - Website: https://stiffperson.org/
Other Organizations
- Autoimmune Association
- 19176 Hall Route, Suite 130
- Clinton Township, MI 48038 U.s.
- Phone: (586) 776-3900
- Toll-free: (888) 852-3456
- Email:
[e-mail protected] - Website: https://autoimmune.org
- Genetic and Rare Diseases (GARD) Information Middle
- PO Box 8126
- Gaithersburg, Dr. 20898-8126
- Phone: (301) 251-4925
- Toll-complimentary: (888) 205-2311
- Website: http://rarediseases.info.nih.gov/GARD/
- Living With Stiff Person Syndrome
- Phone: (904) 375-9385
- Email:
[e-mail protected] - Website: https://world wide web.livingwithsps.com/
- Movement Disorder Club
- 555 E. Wells Street
- Suite 1100
- Milwaukee, WI 53202-3823
- Phone: (414) 276-2145
- Email:
[email protected] - Website: http://www.movementdisorders.org
- NIH/National Plant of Neurological Disorders and Stroke
- P.O. Box 5801
- Bethesda, MD 20824
- Telephone: (301) 496-5751
- Toll-gratis: (800) 352-9424
- Website: http://www.ninds.nih.gov/
- Stiff Human Syndrome Support group
- 75 Normandy Avenue
- East Yorkshire, HU17 8PF United kingdom
- Phone: (148) 286-8881
- E-mail:
[email protected] - Website: http://www.smssupportgroup.co.uk/
- Stiff Person Syndrome
References
TEXTBOOKS
Newsome SD. Other Proven and Putative Autoimmune Disorders of the CNS: Anti-GAD Associated Neurological Disorders, Potent-person syndrome and Progressive Encephalopathy with Rigidity and Myoclonus (PERM). Neurobiology of Disease, 2nd edition. Johnston MV, Adams HP, Fatemi A, editors. 2016. Oxford Universtiy Press, pp. 675-682.
Duddy ME, Baker MR. Strong Person Syndrome. In: Immune-mediated Neurological Diseases, Pourmand R. editor. 2009 S. Karger AG, Basel (Switzerland). pp. 147-165.
Gershanik Os. Stiff-Person Syndrome. In: Movement Disorders: Neurological Principles & Exercise, Watts RL, Koller WC, editors. 2004 The McGraw-Colina Companies, pp. 799-812.
Floeter MK. Strong Person Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:588-589.
Rowland LP. Ed. Merritt’south Neurology. 10th ed. Lippincott Williams & Wilkins. Philadelphia, PA. 2000:761-762.
JOURNAL ARTICLES
Sabatino J, Newsome SD. Stiff person syndrome masquerading as multiple sclerosis. J Neurol Sci. 2017;Jan xv;372:297-299.
Benavides D, Newsome SD. Serotonin-Norepinephrine reuptake inhibitors may exacerbate potent-person syndrome. Neurology. 2016;Aug 29;3(v):e281.
Dupond JL, Essalmi L, Gil H, Meaux-Ruault North, Hafsaoui C. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci. 2010;17:389-391.
Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;17:1291-1292.
Raju R, Foote J, Banga JP, et al. Analysis of GAD65 autoantibodies in potent-person syndrome. J Immunol. 2005;175:7755-7762.
Baker MR, Das G, Isaacs J, Fawcett PRW, Bates D. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry. 2005;76:999-1001.
Murinson, BB. Stiff-person syndrome. The Neurologist. 2004;10:131-137.
Murinson, BB, Butler, M, Gleason, S, et al. Markedly elevated GAD antibodies in SPS. Neurology. 2004;63:2146-2148.
Dalakas MD. Intravenous immunoglobulin in autoimmune neurological diseases. JAMA. 2004;291:2367-2375.
Meinck HM, Thompson PD. Strong man syndrome and related atmospheric condition. Mov Disord. 2002;17:853-866.
Dalakas MC, Fujii Chiliad, Li M, et al. High-dose intravenous allowed globulin for Potent-person syndrome. North Engl J Med. 2001;345:1870-1876.
Dalakas MC, Fujii M, Li K, McElroy B. The clinical specrum of anti-GAD antibiotic-positive patients with strong-person syndrome. Neurology. 2000;55:1531-1535.
Alberca R, Romero M, Chaparro J. Jerking stiff-man syndrome. J Neurol Neurosurg Psychiatry. 1982;45:1159-1160.
Cyberspace
Rodgers-Neame NT. Potent Person Syndrome. Medscape Updated: May 30, 2017. Available at: http://emedicine.medscape.com/commodity/1172135-overview Accessed November 13, 2017.
National Institute of Neurological Disorders and Stroke. Stiff-Person Syndrome Information Folio. Content last reviewed July x, 2017. Bachelor at: https://www.ninds.nih.gov/Disorders/All-Disorders/Stiff-Person-Syndrome-Information-Folio. Accessed November 13, 2017.
Johns Hopkins Medicine. Potent Person Syndrome Center.
https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/stiff-person-syndrome/alphabetize.html . Accessed January 8, 2018.
Years Published
1987, 1989, 1991, 1996, 1997, 1998, 1999, 2000, 2001, 2004, 2010, 2017
The information in NORD’s Rare Illness Database is for educational purposes but and is non intended to replace the communication of a medico or other qualified medical professional person.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may non be reproduced, copied, downloaded or disseminated, in any style, for whatsoever commercial or public purpose, without prior written authorization and blessing from NORD. Individuals may print one hard copy of an individual disease for personal utilise, provided that content is unmodified and includes NORD’south copyright.
National Arrangement for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100
Stiff Muscles Are Characterized by __________
Source: https://rarediseases.org/rare-diseases/stiff-person-syndrome/